Dr. Reddy's Laboratories Launches Tetrabenazine Tablets in US
7 February 2018 - - Hyderabad, India-based integrated pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has launched Tetrabenazine Tablets, a therapeutic equivalent generic version of Xenazine (tetrabenazine) in the US market, approved by the US Food and Drug Administration, the company said.
Tetrabenazine Tablets are a therapeutic equivalent generic version of Xenazine (tetrabenazine) ,a registered trademark of Valeant Pharmaceuticals Luxembourg S.A.R.L.
Dr. Reddy's Tetrabenazine Tablets are available in strengths of 12.5 mg and 25 mg, each strength is available in a bottle count size of 112.
Dr. Reddy's is committed to providing affordable and innovative medicines through its three businesses - pharmaceutical services and active ingredients, global generics, and proprietary products.
The company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, and differentiated formulations. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
Dr. Reddy's operates in markets across the globe, including the US, India, Russia and CIS countries, and Europe.